Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to address the need for regulation and oversight of therapeutic goods, ensuring that such goods meet safety, efficacy, and quality standards before being made available to the public. This legislation established a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and tissue products, with the overarching objective of protecting public health by ensuring that these goods are of an acceptable standard and pose no unacceptable risk to consumers. The Act provides the Therapeutic Goods Administration (TGA) with the authority to control the supply and advertising of therapeutic goods, as well as to monitor their quality, performance, and safety. The Act also aims to facilitate timely access to therapeutic goods that are needed for medical purposes while ensuring that the rights and safety of consumers are safeguarded. The gazetted notice from the Therapeutic Goods Administration under the Therapeutic Goods Act 1989 details the grant of licences to specific entities for the manufacture of therapeutic goods. These licences are granted to Cyclotek Melbourne Pty Ltd, Medical Developments International Limited, and SA Pathology, a business unit of Adelaide Health Service. Each entity is granted a licence to manufacture therapeutic goods at specified locations, with each licence number provided to identify the entity and the scope of its manufacturing authorisation. This action by the TGA is in accordance with the legislative framework established by the Therapeutic Goods Act 1989, which aims to ensure that only those entities meeting stringent regulatory standards are permitted to manufacture therapeutic goods, thereby upholding the safety and quality of goods available to the Australian public.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, or importation of therapeutic goods within Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. The Act is of Commonwealth jurisdiction, thereby extending its reach across the entire nation and ensuring a consistent regulatory framework for therapeutic goods. This legislation applies to both businesses and individuals who engage in the production and distribution of these goods. Notably, the Act includes provisions for licensing and regulates the manufacturing processes to ensure that therapeutic goods meet safety, quality, and efficacy standards. The geographic reach of the Therapeutic Goods Act is national, meaning it applies to all states and territories within Australia. Exclusions and exemptions are detailed within the Act and may apply to certain categories of goods or specific types of activities, but these are carefully delineated to avoid any ambiguity. The Act may also extend its application through subordinate instruments, such as regulations or codes, which provide further detail and operational guidance for compliance. These instruments help to clarify the Act's provisions and ensure consistent application across various sectors and regions.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes various provisions that govern the regulation of therapeutic goods in Australia. Specifically, section 38 of the Act allows the Secretary of the Department of Health, Therapeutic Goods Administration (TGA) to grant licences to manufacturers of therapeutic goods. This particular gazette, C2018G00223, lists companies that have been granted such licences, including Cyclotek Melbourne Pty Ltd (Licence No. MI-2015-LI-08410-1), Medical Developments International Limited (Licence No. MI-2016-LI-04143-1), and SA Pathology, a business unit of Adelaide Health Service (Licence No. MI-2016-LI-09208-1). Entities granted a licence under section 38 of the Act must adhere to certain obligations and requirements. These include, but are not limited to, maintaining high standards of quality and safety in the manufacture of therapeutic goods. This involves implementing and following Good Manufacturing Practices (GMP), ensuring that facilities and processes meet the necessary standards, and maintaining records and documentation as required by the TGA. Licensed manufacturers are also responsible for conducting regular self-inspections and for reporting any incidents or non-compliance to the TGA. Failure to comply with the requirements of the Therapeutic Goods Act 1989, or to maintain the standards set out in the licence, can lead to serious consequences. Under the Act, breaches can result in both civil and criminal penalties. For example, individuals or companies found to have manufactured therapeutic goods in a manner that does not meet the required standards can face fines of up to $1.1 million for a corporation, or $220,000 for an individual, as per section 34AA of the Act. Additionally, section 36AB of the Act allows for imprisonment for up to five years for individuals who are found guilty of serious or repeated breaches. These penalties underscore the importance of compliance with the Act and the obligations of licensed manufacturers.